CLYM Climb Bio, Inc.: רווח למניה בשנים עשר החודשים האחרונים

The fundamental TTM net income per share in the chronology of the indicator on the GURU.Markets chart is based on the potential of B-cell therapy for patients with autoimmune pathologies, where -0.82 expresses the latest level of the metric. Climb Bio Inc (CLYM) is creating a closed patent perimeter through the development of monoclonal antibodies, while seamlessly delegating clinical trials to external contractors without losing control over intellectual property.

Investors utilize this indicator to assess the real yield of each stock, determining the business's intrinsic resilience to market shocks. The calculation of net income per share over 12 months is based on trailing income, which in the case of Climb Bio Inc (CLYM) may stagnate due to sanction restrictions and logistical disruptions during the conduct of global clinical trials.